Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 335

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 335
---
     | demonstrating the safety and efficacy of FYARRO to the satisfaction of the FDA and obtaining regulatory approval                                         
 for FYARRO for other indications and for any other product candidates that we may develop in the future, if any, for which there is a commercial market; |

| • |     | launching and successfully commercializing FYARRO or any other product candidates that we may develop in the                                            
 future following any regulatory approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators; |

| • |     | maintaining a commercially viable supply of, and manufacturing relationships with third parties that can provide                                                                                                  
 adequate, in both amount and quality, products and services to support clinical development and meet the market demand for FYARRO or any other product candidates that we may develop in the future, if approved; |

| • |     | completing development activities successfully and on a timely basis; |

| • |     | obtaining additional regulatory and marketing approvals for FYARRO for additional indications; |

| • |     | our ability to complete investigational new drug (“IND”) application enabling studies and successfully                                                                                                                         
 submit INDs or IND supplements or comparable applications, which become effective without any objections by the FDA or comparable regulatory authorities before commencing a clinical trial for any future product candidates; |

| • |     | establishing and maintaining relationships with contract research organizations (“CROs”) and clinical                          
 sites for the clinical development of FYARRO in other indications and any other future product candidates that we may develop; |

| • |     | timely receipt of regulatory approvals from applicable regulatory authorities for any product candidates for 
 which we successfully complete clinical development;                                                         |

| • |     | developing or contracting for an efficient and scalable manufacturing process for future product candidates, 
 including obtaining finished products that are appropriately packaged for sale;                              |

| • |     | negotiating and maintaining an adequate price for FYARRO or any future product candidates, both in the United 
 States and in foreign countries where our products are commercialized;                                        |

| • |     | a continued acceptable safety profile following any regulatory approval of product candidates; |

| • |     | commercial acceptance of product candidates by patients, the medical community and third-party payors; |

| • |     | obtaining coverage and adequate reimbursement by third-party payors for FYARRO or any future product candidates; |

| • |     | satisfying any required post-regulatory approval commitments to applicable regulatory authorities; |

- 234 -

| • |     | identifying